Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study

Background Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited. Methods This retro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pei-Yuan Su, Wei-Wen Su, Yu-Chun Hsu, Siou-Ping Huang, Hsu-Heng Yen
Formato:	article
Lenguaje:	EN
Publicado:	PeerJ Inc. 2021
Materias:	Tenofovir Disoproxil Fumarate Tenofovir alafenamide Chronic hepatitis B Switch Medicine R
Acceso en línea:	https://doaj.org/article/455a0350dec340fd9e5ad6662d46c136
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:455a0350dec340fd9e5ad6662d46c136
record_format	dspace
spelling	oai:doaj.org-article:455a0350dec340fd9e5ad6662d46c1362021-11-21T15:05:21ZReal-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study10.7717/peerj.125272167-8359https://doaj.org/article/455a0350dec340fd9e5ad6662d46c1362021-11-01T00:00:00Zhttps://peerj.com/articles/12527.pdfhttps://peerj.com/articles/12527/https://doaj.org/toc/2167-8359Background Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited. Methods This retrospective study included 167 nucleos(t)ide analogue (NA)-naive patients with CHB. All the patients received TDF at least 12 months before switching and TAF at least 12 months after switching at a single medical center. The Friedman test with Dunn–Bonferroni post hoc tests and repeated-measures analysis of variance was used to analyze the effect of complete viral suppression, alanine aminotransferase (ALT) level normalization, renal function changes, body weight, and body mass index in the periods before and after switching. Results The mean age and TDF treatment duration were 52 ± 11 years and 2.8 years (interquartile range, 1.51–5.15 years), respectively. The complete viral suppression rate was similar between the time of switching and 48 weeks after switching to TAF (77.8% vs 76%, P = 1.000). The percentage of alanine aminotransferase (ALT) normalization increased from 26.3% at TDF start to 81.4% (P < 0.001) at time of switching and 89.2% at 48 weeks after switching to TAF (P = 0.428). The median estimated glomerular filtration rate decreased from 100.09 mL/min/1.73 m² at TDF start to 91.97 mL/min/1.73 m² (P < 0.001) at the time of switching and stabilized at 48 weeks after switching to TAF (93.47 mL/min/1.73m², P = 1.000). The body weight decreased from 69.2 ± 12.2 kg at TDF start to 67.4 ± 12.1 kg (P < 0.001) at the time of switching to TAF and returned to 68.7 ± 12.7 kg (P < 0.001) 48 weeks thereafter. The body mass index (BMI) decreased from 25 ± 3.3 kg/m² at TDF start to 24.5 ± 3.3 kg/m² (P = 0.002) at the time of switching to TAF and returned to 25.1 ± 3.6 kg/m² (P < 0.001) 48 weeks thereafter. Conclusions Our study showed that switching to TAF from TDF had good antiviral effectiveness and stabilized renal function. The body weight and BMI decreased during TDF therapy and regained after switching to TAF.Pei-Yuan SuWei-Wen SuYu-Chun HsuSiou-Ping HuangHsu-Heng YenPeerJ Inc.articleTenofovir Disoproxil FumarateTenofovir alafenamideChronic hepatitis BSwitchMedicineRENPeerJ, Vol 9, p e12527 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Tenofovir Disoproxil Fumarate Tenofovir alafenamide Chronic hepatitis B Switch Medicine R
spellingShingle	Tenofovir Disoproxil Fumarate Tenofovir alafenamide Chronic hepatitis B Switch Medicine R Pei-Yuan Su Wei-Wen Su Yu-Chun Hsu Siou-Ping Huang Hsu-Heng Yen Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
description	Background Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited. Methods This retrospective study included 167 nucleos(t)ide analogue (NA)-naive patients with CHB. All the patients received TDF at least 12 months before switching and TAF at least 12 months after switching at a single medical center. The Friedman test with Dunn–Bonferroni post hoc tests and repeated-measures analysis of variance was used to analyze the effect of complete viral suppression, alanine aminotransferase (ALT) level normalization, renal function changes, body weight, and body mass index in the periods before and after switching. Results The mean age and TDF treatment duration were 52 ± 11 years and 2.8 years (interquartile range, 1.51–5.15 years), respectively. The complete viral suppression rate was similar between the time of switching and 48 weeks after switching to TAF (77.8% vs 76%, P = 1.000). The percentage of alanine aminotransferase (ALT) normalization increased from 26.3% at TDF start to 81.4% (P < 0.001) at time of switching and 89.2% at 48 weeks after switching to TAF (P = 0.428). The median estimated glomerular filtration rate decreased from 100.09 mL/min/1.73 m² at TDF start to 91.97 mL/min/1.73 m² (P < 0.001) at the time of switching and stabilized at 48 weeks after switching to TAF (93.47 mL/min/1.73m², P = 1.000). The body weight decreased from 69.2 ± 12.2 kg at TDF start to 67.4 ± 12.1 kg (P < 0.001) at the time of switching to TAF and returned to 68.7 ± 12.7 kg (P < 0.001) 48 weeks thereafter. The body mass index (BMI) decreased from 25 ± 3.3 kg/m² at TDF start to 24.5 ± 3.3 kg/m² (P = 0.002) at the time of switching to TAF and returned to 25.1 ± 3.6 kg/m² (P < 0.001) 48 weeks thereafter. Conclusions Our study showed that switching to TAF from TDF had good antiviral effectiveness and stabilized renal function. The body weight and BMI decreased during TDF therapy and regained after switching to TAF.
format	article
author	Pei-Yuan Su Wei-Wen Su Yu-Chun Hsu Siou-Ping Huang Hsu-Heng Yen
author_facet	Pei-Yuan Su Wei-Wen Su Yu-Chun Hsu Siou-Ping Huang Hsu-Heng Yen
author_sort	Pei-Yuan Su
title	Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
title_short	Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
title_full	Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
title_fullStr	Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
title_full_unstemmed	Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
title_sort	real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis b: a retrospective study
publisher	PeerJ Inc.
publishDate	2021
url	https://doaj.org/article/455a0350dec340fd9e5ad6662d46c136
work_keys_str_mv	AT peiyuansu realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT weiwensu realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT yuchunhsu realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT sioupinghuang realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT hsuhengyen realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy
_version_	1718418820338548736

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study

Ejemplares similares